trending Market Intelligence /marketintelligence/en/news-insights/trending/6hleivw6akcevkz1xaahcw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CSPC Pharmaceutical enters licensing deal for blood cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

CSPC Pharmaceutical enters licensing deal for blood cancer drug

CSPC Pharmaceutical Group Ltd. signed a licensing and commercialization agreement to advance SCT400, Sinocelltech Ltd.'s investigational treatment for a certain type of blood cancer.

Sinocelltech is a Beijing-based biotechnology developing SCT400 in late-stage trials in China to treat non-Hodgkin lymphoma, a group of blood cancers that begin in the white blood cells called lymphocytes.

The deal grants CSPC the exclusive right to apply for SCT400's approval in China, including Hong Kong, Macau and Taiwan. The company will also own the drug's license and will be able to market SCT400 in the covered countries within a 15-year period following its regulatory approval.

Under the terms of the agreement, CSPC will give Sinocelltech up-front and development milestone payments of up to 650 million yuan, subject to the approval of SCT400 in the countries covered. The company will also make milestone payments tied to sales of the medicine, once commercialized.

The biologics license application for SCT400 is expected to be filed in the first quarter of 2019.

China-based CSPC is a pharmaceutical group engaged in the manufacturing and commercialization of innovative drugs, common generic drugs and bulk drugs.

As of Oct. 5, US$1 was equivalent to 6.87 yuan.